Cabaletta Bio, Inc. Common Stock
Here’s whether Cabaletta Bio, Inc. Common Stock (CABA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+3.42% over 10 days); strong 1-year return of +67.2%. Concerns: below the 50-day MA (medium-term momentum negative); RSI 20 — oversold; 3-month momentum negative (-5.9%); declining volume on rally — weak conviction (0.75x 30d avg). Currently 28.8% off its 52-week high. Score: +0/7.
CABA is holding above its long-term 200-day MA ($2.73) but has slipped below the 50-day MA ($3.37), pointing to short-term weakness in an otherwise intact trend. An RSI of 20.4 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +67.2% compares to +22.9% for SPY (beat the market by 44.4%). The current 28.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.